RMDRESMED INC

NYSE resmed.com


$ 191.71 $ 5.05 (2.71 %)    

Thursday, 27-Jun-2024 15:59:55 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 191.58
$ 188.47
$ 0.00 x 0
$ 0.00 x 0
$ 188.26 - $ 192.46
$ 131.19 - $ 227.55
1,262,555
na
28.25B
$ 1.02
$ 29.48
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-25-2024 03-31-2024 10-Q
2 01-25-2024 12-31-2023 10-Q
3 10-26-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-K
5 04-28-2023 03-31-2023 10-Q
6 01-27-2023 12-31-2022 10-Q
7 10-28-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-K
9 04-28-2022 03-31-2022 10-Q
10 01-27-2022 12-31-2021 10-Q
11 10-28-2021 09-30-2021 10-Q
12 08-17-2021 06-30-2021 10-K
13 04-30-2021 03-31-2021 10-Q
14 01-29-2021 12-31-2020 10-Q
15 10-30-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-K
17 05-01-2020 03-31-2020 10-Q
18 01-31-2020 12-31-2019 10-Q
19 10-25-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-K
21 05-03-2019 03-31-2019 10-Q
22 02-01-2019 12-31-2018 10-Q
23 10-26-2018 09-30-2018 10-Q
24 08-17-2018 06-30-2018 10-K
25 04-27-2018 03-31-2018 10-Q
26 01-24-2018 12-31-2017 10-Q
27 10-27-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-K
29 04-28-2017 03-31-2017 10-Q
30 01-25-2017 12-31-2016 10-Q
31 10-28-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-K
33 04-29-2016 03-31-2016 10-Q
34 01-28-2016 12-31-2015 10-Q
35 10-27-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-K
37 04-29-2015 03-31-2015 10-Q
38 01-30-2015 12-31-2014 10-Q
39 10-31-2014 09-30-2014 10-Q
40 08-08-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-downgrades-resmed-to-perform

Oppenheimer analyst Suraj Kalia downgrades ResMed (NYSE:RMD) from Outperform to Perform.

 why-resmed-shares-are-trading-lower-monday

ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatmen...

 semiconductor-nvidia-woes-deepen-nasdaq-100-slips-dow-rallies-bitcoin-sinks-to-60400-whats-driving-markets-monday

Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off he...

 citigroup-downgrades-resmed-to-neutral

Citigroup analyst Mathieu Chevrier downgrades ResMed (NYSE:RMD) from Buy to Neutral.

 nasdaq-futures-slip-as-nvidia-sell-off-continues-sp-500-futures-hold-up-analyst-says-valuations-will-go-parabolic-and-it-will-be-a-perfect-time-to-sell

The U.S.

 needham-reiterates-buy-on-resmed-maintains-236-price-target

Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Buy and maintains $236 price target.

 oppenheimer-maintains-outperform-on-resmed-lowers-price-target-to-200

Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $205 to $200.

 rbc-capital-maintains-sector-perform-on-resmed-raises-price-target-to-200

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $187 t...